Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Application of Lobaplatin in Trans-catheter Arterial Chemoembolization for Primary Hepatic Carcinoma

  • Wang, Nan (Invasive Technology Department, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Techonology) ;
  • Lv, Yin-Zhang (Invasive Technology Department, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Techonology) ;
  • Xu, An-Hui (Invasive Technology Department, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Techonology) ;
  • Huang, Yan-Rong (Invasive Technology Department, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Techonology) ;
  • Peng, Ling (Invasive Technology Department, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science & Techonology) ;
  • Li, Jia-Rui (Invasive Technology Department, The First Hospital of Jilin University)
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To explore the efficiency of single application of lobaplatin in tran-scatheter arterial chemoembolization (TACE) for patients with a primary hepatic carcinoma who were unable or unwilling to undergo surgery. Methods: 173 patients with primary hepatic carcinoma diagnosed by imaging or pathology were randomly divided into experimental and control groups and respectively treated with lobaplatin and pirarubicin hydrochloride as chemotherapeutic drugs for TACE. The amount of iodipin was regulated according to the tumor number and size, and then gelatin sponge or polyvinyl alcohol particles were applied for embolisms. The efficiency of treatment in the two groups was compared with reference to survival time and therapeutic response. Results: The experimental group (single lobaplatin as chemotherapy drug) was superior to control group (single pirarubicin hydrochloride as chemotherapy drug) in the aspects of survival time and therapeutic response, with statistical significance. Conclusions: Single lobaplatin can be as a chemotherapy drug in TACE and has better efficiency in the aspects of mean survival time and therapeutic response, deserving to be popularized in the clinic.

Keywords

References

  1. Agnello F, Salvaggio G, Cabibbo G, et al (2013). Imaging appearance of treated hepatocellular carcinoma. World J Hepatol, 5, 417-24. https://doi.org/10.4254/wjh.v5.i8.417
  2. Ali I, Wani WA, Saleem K, et al (2013). Platinum compounds: a hope for future cancer chemotherapy. Anticancer Agents Med Chem, 13, 296-306. https://doi.org/10.2174/1871520611313020016
  3. Cescon M, Cucchetti A, Ravaioli M, et al (2013). Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol, 58, 609-18. https://doi.org/10.1016/j.jhep.2012.09.021
  4. Cui L, Liu XX, Jiang Y, et al (2012). Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients. Asian Pac J Cancer Prev, 13, 6257-61. https://doi.org/10.7314/APJCP.2012.13.12.6257
  5. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of Loubo (R) (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  6. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
  7. Engel JB, Martens T, Hahne JC, et al (2012). Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anticancer Drugs, 23, 426-36. https://doi.org/10.1097/CAD.0b013e32834fb8ce
  8. Giunchedi P, Maestri M, Gavini E, et al (2013). Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1. Expert Opin Drug Deliv, 10, 679-90. https://doi.org/10.1517/17425247.2013.770733
  9. Giunchedi P, Maestri M, Gavini E, et al (2013). Transarterial chemoembolization of hepatocellular carcinoma--agents and drugs: an overview. Part 2. Expert Opin Drug Deliv, 10, 799-810. https://doi.org/10.1517/17425247.2013.796359
  10. Gomes MA, Priolli DG, Tralhao JG, et al (2013). Hepatocellular carcinoma: Epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras, 59, 514-24. https://doi.org/10.1016/j.ramb.2013.03.005
  11. Hao YX, Wang JP, Zhao LF (2013). Associations Between Three Common MicroRNA Polymorphisms and Hepatocellular Carcinoma Risk in Chinese. Asian Pac J Cancer Prev, 14, 6601-4. https://doi.org/10.7314/APJCP.2013.14.11.6601
  12. Hu DY, Li Z, Wang N, et al (2004). Comparative study of lowdosage and routine dosage chemotherapeutic drugs on liver cancer through transcatheter arterial chemoembolization. J Clin Radiol, 23, 502-6.
  13. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  14. Huang ZJ, Zhou MG, Wang LJ (2007). Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China. Disease Surveillance, 22, 242-5.
  15. Kong WD, Cao JM, Xu J, et al (2012). Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients. Asian Pac J Cancer Prev, 13, 4757-61. https://doi.org/10.7314/APJCP.2012.13.9.4757
  16. Li C, Zhang Y, Zhou J, et al (2013). Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study. World J Surg Oncol, 11, 222. https://doi.org/10.1186/1477-7819-11-222
  17. Li KW, Li X, Wen TF, et al (2013). The effect of postoperative TACE on prognosis of HCC: an update. Hepatogastroenterology, 60, 248-51.
  18. Liu D, He C, Wang AZ, et al (2013). Application of liposomal technologies for delivery of platinum analogs in oncology. Int J Nanomedicine, 8, 3309-19.
  19. Mckeage MJ (2001). Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs, 10, 119-28. https://doi.org/10.1517/13543784.10.1.119
  20. Minami Y, Kudo M (2013). Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology, 84, 58-63. https://doi.org/10.1159/000345891
  21. Murata S, Mine T, Ueda T, et al (2013). Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal, 2013, 1-8.
  22. Qian J, Qin SK, Yang AZ, et al (2009). Experimental research about different inhibition of platinum complexes in human hepatocellular carcinoma cell line. Chin Clin Oncol, 14, 414-7.
  23. Shi M, Chen JA, Lin XJ, et al (2009). Prospective Randomized Controlled Study of Transarterial Chemoembolization with Doxorubicin versus Doxorubicin/Lobaplatin/Mitomycin Combination for Unresectable Hepatocellular Carcinoma. Chin J Clin Oncol, 36, 9-13.
  24. Shi M, Lu LG, Fang WQ, et al (2013). Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst, 105, 59-68. https://doi.org/10.1093/jnci/djs464
  25. Wang Y, Zheng WL, Ma WL (2012). Lobaplatin inhibits the proliferation of hepatollular carcinoma through p53 apoptosis axis. Hepat Mon, 12, e6024.
  26. Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000. https://doi.org/10.7314/APJCP.2013.14.10.5995
  27. Wu Q, Qin SK, Teng FM, et al (2010). Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells. J Hematol Oncol, 3, 43. https://doi.org/10.1186/1756-8722-3-43
  28. Xie CY, Xu YP, Jin W, et al (2012). Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anticancer Drugs, 23, 698-705. https://doi.org/10.1097/CAD.0b013e328352cc10
  29. Yang LQ, Qin SK (2009). Progression of lobaplatin as the third generation platinum drug. Chin Clin Oncol, 14, 1134-9.
  30. Zhou B, Shan H, Zhu KS, et al (2010). Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol, 21, 333-8. https://doi.org/10.1016/j.jvir.2009.11.006

Cited by

  1. Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2681
  2. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5957
  3. MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma vol.20, pp.10, 2016, https://doi.org/10.1089/gtmb.2016.0073
  4. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer vol.9, pp.1, 2018, https://doi.org/10.1038/s41467-018-03210-2
  5. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma vol.97, pp.18, 2018, https://doi.org/10.1097/MD.0000000000010613